ArticleEncephalitis (Seoul, Korea)2026
Brain 18F-fluorodeoxyglucose positron emission tomography/computed tomography in COVID 19-associated autoimmune encephalitis: a case report.
Article in Encephalitis (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19)-associated encephalitis is a rare but severe neurological complication. Conventional diagnostic tools, such as magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) studies, may yield normal results despite significant functional brain impairment. Brain positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) has emerged as a valuable adjunctive imaging modality in such cases. We report the case of a 54-year-old woman with COVID-19 who presented with anosmia, ageusia, and altered behavior. Neurological examination revealed cognitive deficits, including bradyphrenia and mixed aphasia. Routine MRI and CSF analyses were unremarkable. However, brain 18F-FDG PET/CT revealed cortical hypometabolism in frontal and temporal lobes and cerebellar changes, consistent with immune-mediated encephalitis. The patient received immunosuppressive therapy with corticosteroids and intravenous immunoglobulin, leading to gradual clinical improvement and complete recovery at 3 months. This case highlights the diagnostic challenge of COVID-19-associated encephalitis when routine studies are inconclusive. PET/CT functional imaging can detect metabolic brain changes not apparent on structural imaging, supporting immune-mediated pathogenesis. Early recognition and immunotherapy may improve neurological outcomes. To conclude, brain 18F-FDG PET/CT is a useful diagnostic adjunct in COVID-19-related encephalitis with normal MRI and negative CSF, aiding timely diagnosis and treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.